1 in 3 Bladder Cancer Patients Wait Over 60 Days

In a Columbia study, many patients waited more than two months for pre-surgery chemotherapy, often due to added testing and care transfers.

Updated on Nov. 7, 2026 in Cancer

A long pale hospital corridor with a row of closed doors and a single gurney, lit by soft daylight from a window at the far end.
Columbia University researchers found 35% of patients with muscle-invasive bladder cancer waited more than 60 days for pre-surgery chemotherapy in a 2026 ASCO-presented study. AI Illustration. Upload story photo >

Columbia University researchers reported that 35% of patients with muscle-invasive bladder cancer waited more than 60 days to begin neoadjuvant chemotherapy, based on a retrospective review of 117 patients treated between 2014 and 2024. The findings were presented at the 2026 ASCO Quality Care Symposium in Boston, and they point to care-coordination steps that may be addressable for patients in the United States.

Why it matters

Neoadjuvant chemotherapy is given before surgery, so delays can affect how patients move through their cancer treatment plan. The study suggests many of these waits stem from logistics such as additional testing, second opinions, and transfers of care rather than from clinical decisions alone, which makes them a potential target for health systems to improve.

This retrospective study reviewed 117 patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy at Columbia University Irving Medical Center between 2014 and 2024, with patients identified through electronic health records and reasons for delay determined by chart review. The primary outcome was a delay of more than 60 days from pathologic diagnosis to first systemic chemotherapy, and the study found no covariates that significantly predicted delay.

The players

Columbia University Irving Medical Center

A major academic medical center in New York City whose researchers conducted the retrospective review of bladder cancer treatment timing.

American Society of Clinical Oncology (ASCO)

The leading professional society for cancer doctors, which hosts annual meetings and quality-of-care symposia on oncology practice.

The details

Delays were identified by measuring the interval from pathologic diagnosis to the first systemic chemotherapy dose. The most common causes were additional imaging or procedures, which accounted for 29.2% of delays, and second opinions or transfer of care, which accounted for 22.0%. Comorbidity management caused 19.5%, psychosocial factors 7.3%, and clinical trial enrollment 4.9%, while 17.1% of delays had no identified cause.

Timeline

  1. 2014-2024: Patients treated with neoadjuvant chemotherapy were identified for the retrospective review.

  2. October 16-17, 2026: Findings were presented at the 2026 ASCO Quality Care Symposium in Boston.

Health Landscape

Neoadjuvant chemotherapy for muscle-invasive bladder cancer is part of a treatment pathway where timing can matter, and the 2026 ASCO Quality Care Symposium is a recurring venue for measuring how well such care is delivered. The study adds bladder cancer to the body of quality-of-care research that examines delays between diagnosis and systemic treatment.

If you or a family member has been diagnosed with muscle-invasive bladder cancer, it is reasonable to ask your oncology team to confirm the timeline for starting chemotherapy and what steps are needed before it begins. Patients who are offered a second opinion or a transfer of care should understand that these steps can add time, and they are worth discussing with your doctor.

The takeaway

Delays before treatment for bladder cancer often reflect coordination and logistics, not only medical choices, so patients can ask their care team about the expected treatment timeline. Discuss any planned second opinions or added testing with your physician to understand how they affect when treatment starts.

Further reading

For more on how cancer care pathways are studied and improved, explore our Cancer coverage.

Source note: This article includes information reported by Oncnursingnews.